J. Goldman & CO LP Pro Qr Therapeutics N.V. Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $91,908 - $856,786	-102,120 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $621,020 - $796,567	-94,380 Reduced 48.03%	102,120 $818,000
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $1.01 Million - $1.66 Million	196,500 New	196,500 $1.65 Million
Q3 2018 Nov 14, 2018	SELL	$6.45 - $21.6 $1.43 Million - $4.8 Million	-222,284 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.95 - $7.45 $655,737 - $1.66 Million	222,284 New	222,284 $1.62 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.